| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| Peter Molloy | Q71190226 | ||
| P2093 | author name string | Yi Li | |
| Paul F Robbins | |||
| Richard A Morgan | |||
| Zhili Zheng | |||
| Yangbing Zhao | |||
| Bent K Jakobsen | |||
| Qiong J Wang | |||
| Steven M Dunn | |||
| Alan D Bennett | |||
| Lawrence Y L Yu | |||
| P2860 | cites work | Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 |
| How a single T cell receptor recognizes both self and foreign MHC | Q27644381 | ||
| Cancer/testis antigens: an expanding family of targets for cancer immunotherapy | Q28215652 | ||
| In vitro evolution of a T cell receptor with high affinity for peptide/MHC. | Q30861962 | ||
| TCRs with high affinity for foreign pMHC show self-reactivity | Q30873107 | ||
| Selecting and maintaining a diverse T-cell repertoire | Q33783983 | ||
| The MHC reactivity of the T cell repertoire prior to positive and negative selection. | Q34418401 | ||
| The specificity of TCR/pMHC interaction | Q34493013 | ||
| High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation | Q34657652 | ||
| Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions | Q34669675 | ||
| The cancer/testis genes: review, standardization, and commentary. | Q35635779 | ||
| Long-term T cell memory requires the surface expression of self-peptide/major histocompatibility complex molecules | Q35979288 | ||
| Differences in the level of expression of class I major histocompatibility complex proteins on thymic epithelial and dendritic cells influence the decision of immature thymocytes between positive and negative selection | Q36067105 | ||
| Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines | Q36327142 | ||
| CD8(-) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. | Q36369627 | ||
| A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex | Q36369989 | ||
| CD8beta endows CD8 with efficient coreceptor function by coupling T cell receptor/CD3 to raft-associated CD8/p56(lck) complexes | Q36370077 | ||
| High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens | Q36471584 | ||
| Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface | Q36740232 | ||
| Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. | Q37629901 | ||
| Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors | Q40271802 | ||
| Clustering class I MHC modulates sensitivity of T cell recognition | Q40278155 | ||
| Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells | Q40320783 | ||
| Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor. | Q40362192 | ||
| Cutting edge: single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells | Q40743368 | ||
| The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. | Q40794740 | ||
| Recognition of the major histocompatibility complex restriction element modulates CD8(+) T cell specificity and compensates for loss of T cell receptor contacts with the specific peptide | Q40967335 | ||
| High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. | Q40978441 | ||
| CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes | Q41145528 | ||
| T-cell-receptor affinity and thymocyte positive selection | Q41192128 | ||
| In thymic selection, peptide diversity gives and takes away | Q41585792 | ||
| Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells | Q41864164 | ||
| Peripheral T cell survival requires continual ligation of the T cell receptor to major histocompatibility complex-encoded molecules | Q41922560 | ||
| Evidence for a differential avidity model of T cell selection in the thymus | Q45155438 | ||
| Ligand recognition by alpha beta T cell receptors | Q46222293 | ||
| The T cell repertoire may be biased in favor of MHC recognition. | Q48356651 | ||
| Directed evolution of human T-cell receptors with picomolar affinities by phage display. | Q51538190 | ||
| The quantitative assessment of MHC II on thymic epithelium: implications in cortical thymocyte development. | Q53600866 | ||
| Tumor-specific cytolysis by lymphocytes infiltrating human melanomas | Q69738303 | ||
| TCR triggering: co-receptor-dependent or -independent? | Q79329830 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phage display | Q896217 |
| P304 | page(s) | 5845-5854 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines | |
| P478 | volume | 179 |
| Q39621147 | A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. |
| Q39394934 | A generalized framework for computational design and mutational scanning of T-cell receptor binding interfaces |
| Q39785306 | A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity |
| Q34670378 | A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control |
| Q60913472 | A rare population of tumor antigen-specific CD4CD8 double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells |
| Q83225759 | A tissue-like platform for studying engineered quiescent human T-cells' interactions with dendritic cells |
| Q37257207 | Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology |
| Q37778694 | Adoptive cell therapy: genetic modification to redirect effector cell specificity. |
| Q36028047 | Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice |
| Q47793265 | Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity |
| Q52804817 | An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. |
| Q37225251 | An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. |
| Q34086610 | Antigen potency and maximal efficacy reveal a mechanism of efficient T cell activation |
| Q36748257 | CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells |
| Q27646628 | Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor |
| Q34992781 | Calcarea carbonica induces apoptosis in cancer cells in p53-dependent manner via an immuno-modulatory circuit |
| Q38011641 | Cancer therapy with genetically-modified T cells for the treatment of melanoma |
| Q37095348 | Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. |
| Q38205228 | Cell transfer therapy for cancer: past, present, and future |
| Q38777005 | Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir |
| Q34567347 | Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display |
| Q36326582 | Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells |
| Q28269352 | Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance |
| Q34511646 | Clinical application of genetically modified T cells in cancer therapy |
| Q47570358 | Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains |
| Q94562689 | Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics |
| Q36445933 | Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor |
| Q27652612 | Distinct CDR3 conformations in TCRs determine the level of cross-reactivity for diverse antigens, but not the docking orientation |
| Q34436547 | Diversity-oriented approaches for interrogating T-cell receptor repertoire, ligand recognition, and function |
| Q34624124 | Engineering improved T cell receptors using an alanine-scan guided T cell display selection system |
| Q37026759 | Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection |
| Q41199674 | Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes |
| Q90425510 | Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function |
| Q38123667 | Gene-engineered T cells for cancer therapy |
| Q35221732 | Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. |
| Q47438128 | Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro |
| Q26995677 | Genetic engineering with T cell receptors |
| Q55358019 | Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. |
| Q33535905 | HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity |
| Q90322274 | Harnessing neoantigen specific CD4 T cells for cancer immunotherapy |
| Q34463820 | High-avidity T cells are preferentially tolerized in the tumor microenvironment |
| Q28727481 | How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer |
| Q43238571 | Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. |
| Q92665367 | Human T-cell receptor V gene segment of alpha and beta families: A revised primer design strategy |
| Q64111849 | Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display |
| Q38763198 | Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells |
| Q50005900 | Identification of α-fetoprotein-specific T cell receptors for hepatocellular carcinoma immunotherapy |
| Q26774669 | Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens |
| Q90928077 | Improving T Cell Receptor On-Target Specificity via Structure-Guided Design |
| Q35738738 | Improving TCR Gene Therapy for Treatment of Haematological Malignancies |
| Q34626998 | Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune molecules |
| Q36080586 | Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness |
| Q57805467 | Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules |
| Q38930056 | Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+) CD25(-) and CD8(+) T cells attenuates effector function |
| Q39414393 | Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity |
| Q39290133 | MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. |
| Q37691398 | MM-GBSA binding free energy decomposition and T cell receptor engineering |
| Q37766303 | Molecular immunology lessons from therapeutic T-cell receptor gene transfer |
| Q38117139 | Molecular insights for optimizing T cell receptor specificity against cancer |
| Q34047618 | Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition |
| Q37963294 | Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses |
| Q36921230 | Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide |
| Q38335303 | Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions |
| Q46214811 | Phenotypic models of T cell activation |
| Q34598553 | Probing the effector and suppressive functions of human T cell subsets using antigen-specific engineered T cell receptors |
| Q33859524 | Rational design of T cell receptors with enhanced sensitivity for antigen |
| Q27654241 | Rational development of high-affinity T-cell receptor-like antibodies |
| Q34084756 | Rebalancing Immune Specificity and Function in Cancer by T-Cell Receptor Gene Therapy |
| Q28080312 | Recent advances in T-cell engineering for use in immunotherapy |
| Q37197945 | Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression |
| Q35216278 | Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity |
| Q37854072 | Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer |
| Q37107843 | Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies |
| Q36638160 | SHP-1 phosphatase activity counteracts increased T cell receptor affinity |
| Q36713758 | Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions |
| Q39507137 | Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains. |
| Q35205495 | Specific roles of each TCR hemichain in generating functional chain-centric TCR. |
| Q33655849 | Strategies to genetically engineer T cells for cancer immunotherapy |
| Q37951560 | Structural and biophysical determinants of αβ T-cell antigen recognition |
| Q38050477 | Structural and dynamic control of T-cell receptor specificity, cross-reactivity, and binding mechanism |
| Q37165240 | Structure-Based, Rational Design of T Cell Receptors |
| Q37190431 | Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity |
| Q41862429 | Subtle changes in TCRα CDR1 profoundly increase the sensitivity of CD4 T cells |
| Q35659205 | T Cell Receptor Engineering and Analysis Using the Yeast Display Platform |
| Q34115960 | T cell avidity and tumor immunity: problems and solutions |
| Q35533181 | T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells |
| Q38068003 | T cell-based gene therapy of cancer |
| Q27678265 | T-cell Receptor Specificity Maintained by Altered Thermodynamics |
| Q90239126 | T-cell Receptors Engineered De Novo for Peptide Specificity Can Mediate Optimal T-cell Activity without Self Cross-Reactivity |
| Q37363263 | T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity |
| Q28081611 | T-cell receptor gene therapy--ready to go viral? |
| Q35885273 | TCR affinity and specificity requirements for human regulatory T-cell function |
| Q28081699 | TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity |
| Q37384350 | TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. |
| Q27671024 | TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms |
| Q89899513 | TCRs with Distinct Specificity Profiles Use Different Binding Modes to Engage an Identical Peptide-HLA Complex |
| Q90211977 | Targeting the MHC Ligandome by Use of TCR-Like Antibodies |
| Q33698006 | The Goldilocks Model for TCR—Too Much Attraction Might Not Be Best for Vaccine Design |
| Q39130457 | The Principles of Engineering Immune Cells to Treat Cancer |
| Q42321433 | The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy |
| Q53673922 | The clinical potential for koff-rate measurement in adoptive immunotherapy. |
| Q33649735 | Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. |
| Q35353365 | Treating cancer with genetically engineered T cells |
Search more.